GlassScriptPhysician profile
Katie A Barnard
NPI 1871980755
$4,698.45
in general payments reported to CMS, 2019-2025
29 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,072 · 2023: $1,171 · 2024: $1,059 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,394.92 | 2021-2025 | Relistor |
| Abbott Laboratories | $901.66 | 2021-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $654.04 | 2021-2024 | Xtampza, Belbuca |
| Abbvie INC. | $289.20 | 2021-2024 | |
| Nevro Corp. | $209.90 | 2021-2023 | Senza |
| Vertos Medical, INC. | $191.07 | 2021-2024 | Mild Device Kit |
| Valinor Pharma, LLC | $168.24 | 2023-2024 | Movantik |
| Medtronic, INC. | $126.06 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Biotronik Nro, INC. | $109.72 | 2023-2024 | Prospera, Biotronik |
| Spr Therapeutics, INC | $98.97 | 2021-2024 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $77.50 | 2021 | |
| Boston Scientific Corporation | $71.50 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.17 | 2022 | |
| Lilly USA, LLC | $63.29 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $33.51 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $27.02 | 2025 | |
| Pfizer INC. | $26.89 | 2023 | |
| Curonix LLC | $21.63 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $17.65 | 2021 | |
| Redhill Biopharma INC. | $16.56 | 2021 | |
| Painteq LLC | $16.22 | 2024 | Painteq |
| Novartis Pharmaceuticals Corporation | $16.06 | 2021 | |
| Fidia Pharma USA INC. | $15.77 | 2022 | |
| Optinose US, INC. | $15.70 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.23 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.27 | 2024 | Horizant |
| Hikma Pharmaceuticals USA | $14.00 | 2022 | |
| Ibsa Pharma INC. | $13.39 | 2021 | |
| Depuy Synthes Sales INC. | $13.31 | 2023 | Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.